Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Suspicions raised by biology postdoc Margot O’Toole about a few lines of data in a 1986 paper in the journal Cell by former MIT immunologist Thereza Imanishi-Kari, Nobel laureate David Baltimore and several co-workers snowballed into the late 20th century’s most public dispute over fraud and error in science. In 1991 The New York Times called it “A Scientific Watergate,” but a far more apt comparison is available today in the Whitewater investigation. Both the Baltimore saga and the Whitewater inquiry were pushed forward by obsessive, heavy-handed investigators with political agendas; both cases feature prominent targets who acted by turns indignant and contrite; and both matters dragged on interminably, with investigators chasing after details decreasingly related to the original alleged offenses. And just as the Whitewater inquiry long ago grew too convoluted for most citizens to grasp, the Baltimore case hinged on immunological experiments so arcane-and produced so many conflicting interpretations of the allegedly fabricated experimental records-that impartial observers rarely knew what to believe.

Daniel Kevles knows. An eminent historian of science at Caltech (where Baltimore was named president in 1997), Kevles not only examined Imanishi-Kari’s lab notebooks, which document the disputed experiments on the effect of gene transfers on antibody production in mice, but also waded through thousands of pages of testimony and interviewed more than 70 scientists and others caught up in the case, including all the principals. He concludes-as a Public Health Service appeals board did in 1996-that Imanishi-Kari is innocent of fakery. He also argues that Baltimore’s famously combative defense of Imanishi-Kari before muckraking Rep. John Dingell in 1989 congressional hearings was justified, if brash.

Kevles’ book is an opinionated and unsparing one. Kevles argues, for example, that O’Toole, criticized by Imanishi-Kari when she was unable to replicate parts of the gene transfer study, was guided largely by resentment and frustration over her own sputtering scientific career when she later charged that Imanishi-Kari had fudged the data from the original experiments. The scientifically sporting thing for O’Toole to do, he asserts, would have been to design new experiments to test competing hypotheses. “Baltimore…was right to contend that O’Toole’s critique of the Cell paper could be resolved not by argument but only by further research,” he observes. Kevles’ exhaustive critique of O’Toole’s charges and the way the government handled them, on the other hand, probably makes further research on what has gone down in history as “the Baltimore case” unnecessary.

0 comments about this story. Start the discussion »

Tagged: Business

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me